Vitamin D₃ (Cholecalciferol) Repletion and Maintenance Guidelines

Mechanistic Advantage

• Cholecalciferol exhibits higher bioavailability and sustains serum concentrations longer than ergocalciferol, a benefit that is especially important when using intermittent (weekly or monthly) dosing regimens. [1][2]

Repletion Regimens

Severe Deficiency (25(OH)D < 10 ng/mL)

• Administer cholecalciferol 50,000 IU once weekly for 12 weeks, then switch to a maintenance schedule. [1][2]
• Alternative intensive protocol: cholecalciferol 8,000 IU daily for 4 weeks followed by 4,000 IU daily for the next 2 months. 2

Moderate Deficiency (25(OH)D 10–20 ng/mL)

• Give cholecalciferol 50,000 IU once weekly for 8 weeks, then continue with maintenance dosing. [1][2]

Insufficiency (25(OH)D 20–30 ng/mL)

• Provide cholecalciferol 50,000 IU once monthly (≈1,600 IU daily equivalent). [1][2]

Maintenance Dosing

• Standard maintenance: 800–2,000 IU cholecalciferol daily to keep 25(OH)D ≥ 30 ng/mL. 2
• Adults ≥ 60 years: minimum 800 IU daily; 1,000 IU daily is preferred to optimize fracture and fall prevention. 1
• Monthly alternative: 50,000 IU cholecalciferol once each month, providing an equivalent daily dose. [1][2]

Monitoring Protocol

• Measure serum calcium and phosphorus 1 month after initiating or adjusting vitamin D dose, then every 3 months while on therapy. 1
• Once the target 25(OH)D level (≥ 30 ng/mL) is achieved and stable, re‑measure 25(OH)D annually. 1

Special Populations

Chronic Kidney Disease (Stages 3–4)

• Apply the same nutritional cholecalciferol dosing regimens as for the general population; do not substitute active vitamin D analogs (e.g., calcitriol, alfacalcidol) for nutritional deficiency. [1][2]

Safety Considerations

• Discontinue all vitamin D supplementation immediately if corrected serum calcium rises above 10.2 mg/dL (2.54 mmol/L). 1
• Daily cholecalciferol doses up to 4,000 IU are regarded as completely safe for long‑term use; doses up to 10,000 IU have been used safely in CKD patients for more than one year. 2

When Ergocalciferol May Be Used

• If cholecalciferol is unavailable or cost‑prohibitive, ergocalciferol can be employed, but higher cumulative doses are required to achieve equivalent 25(OH)D increases. [1][2]

Common Pitfalls to Avoid

• Do not replace nutritional vitamin D deficiency treatment with active vitamin D analogs, as they bypass physiological regulation and markedly increase the risk of hypercalcemia. [1][2]

Vitamin D Supplementation in CKD Patients

Treatment Strategy

• The American Journal of Kidney Diseases recommends cholecalciferol as the appropriate first-line treatment for vitamin D deficiency in non-dialysis CKD patients 3
• Measure baseline 25(OH)D levels to determine deficiency severity and guide dosing, with a target 25(OH)D level of ≥30 ng/mL to prevent secondary hyperparathyroidism and reduce fracture risk 4, 3
• For severe deficiency (<5 ng/mL), the recommended dosing regimen is 50,000 IU weekly for 12 weeks, then 50,000 IU twice monthly 4
• For mild deficiency (5-15 ng/mL), the recommended dosing regimen is 50,000 IU weekly for 4 weeks, then 50,000 IU twice monthly for 2 months 4
• For insufficiency (16-30 ng/mL), the recommended dosing regimen is 50,000 IU every 4 weeks 4
• Maintenance after repletion: 800-1,000 IU daily (particularly important for patients >60 years) 3

Monitoring Protocol

• Check serum calcium and phosphorus at 1 month after initiating or changing vitamin D dose, then every 3 months 5
• Monitor 25(OH)D levels after completing the loading phase (typically at 3 months) to confirm repletion 5
• Annual 25(OH)D monitoring once replete 5

Critical Considerations

• Vitamin D insufficiency is present in 80-90% of elderly CKD patients, with prevalence reaching 89% in those >65 years 5
• Hip fracture risk reduction of 43% has been demonstrated with vitamin D 800 IU/daily plus calcium in elderly populations 3

Safety Profile

• Doses up to 10,000 IU daily have been used in advanced CKD patients for >1 year without toxicity 4, 3
• Ergocalciferol may be safer than cholecalciferol, though both are acceptable 3

Common Pitfalls to Avoid

• Do NOT use calcitriol or other activated vitamin D analogs to treat nutritional vitamin D deficiency in CKD stages 2-4 4, 3
• Do NOT rely solely on cholecalciferol in dialysis patients with elevated PTH—they need activated vitamin D 6
• Avoid excessive PTH suppression in dialysis patients (target intact PTH >65 pg/mL) to prevent adynamic bone disease 6